The 7 initial formulations are designed to support and enhance memory and brain function, the immune system, energy levels, and overall wellness, while reducing the negative impacts of stress.
November 11, 2020 – Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce its initial seven natural health supplements.
These 7 products will be Havn Life’s first natural health products to launch in 2021. Each product has been thoughtfully formulated with adaptogens and antioxidants to aid in overall health and wellness and support human optimization. The initial product launch includes;
– Mind Mushroom: A blend of four mushrooms, mind is designed to help balance the immune system, fight cell damage and increase energy.
– Bacopa Brain: Bacopa is a powerful plant extract that is clinically proven to support cognitive function and the nervous system.
– Rhodiola Relief: Formulated to support mental focus and mental stamina.
– Cordyceps Perform: Cordyceps mushrooms help support a healthy immune system.
– Chaga Immunity: Chaga mushrooms help stimulate the immune system and control inflammation in the body.
– Reishi Recharge: this multi-purpose mushroom has also been used in Traditional Chinese Medicines to strengthen the heart to reduce fatigue, insomnia and appetite as well as coughs and wheezing.
– Lion’s Mane Memory: Lion’s mane helps maintain and balance the immune system.
“The Havn Life Team has worked diligently to develop formulations that not only enhance and aid in human performance, but also provide overall health and wellness benefits,” said Chief Executive Officer, Tim Moore. “Havn Life’s team has done an incredible job bringing a complete and wide range of initial products to launch in 2021. The team will continue to work on additional formulations and products that will be launched later in 2021.“
Furthermore, the Company has now received approval from Health Canada for all seven products for launch in 2021 and will provide further updates on its initial launch in the Canadian market.
On Behalf of The Board of Directors
Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.
Investor Relations: email@example.com 604 687 7130
Media: firstname.lastname@example.org 778 238 6096
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release
This content was originally published here.